ClinicalTrials.gg
RecruitingNCT07514065Updated Apr 7, 2026

TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy

A Phase 1 interventional study of Treatment arm: TSL2109 capsules。Oral administration。 in Metastatic Castration-Resistant Prostate Cancer Patients, sponsored by Tasly Pharmaceutical Group Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by Tasly Pharmaceutical Group Co., Ltd (part of China Resources Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
78
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 541 studies in Prostatic Neoplasms with a site in China — 281 open to participants now, 342 under way, 51 of them phase 3. Prostatic Neoplasms · China.

Planned enrollment
247th of 435
78 · median 100
Started
2026
with 82 others
Phase 1
97 of 541
54 open now
Primary completion
2026-12
later than 142 of 341 live
Registered
473rd of 541
by date

Among the 541 studies in Prostatic Neoplasms with a site in China, this one is the 247th largest by planned enrollment of the 435 interventional ones that give a count, is one of 83 that started in 2026, is one of 97 in phase 1, reaches primary completion later than 142 of the 341 other live ones, and was the 473rd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

281 of the 541 studies in Prostatic Neoplasms with a site in China are open now. Recruiting first, the newest first:

276 more — sign in →

All 281 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 541 studies in Prostatic Neoplasms with a site in China, or all of them as a file.
02

Study summary

TSL2109 is a novel CDK4/6-DYRK2 dual-target inhibitor developed by Jiangsu Tasly Diyee Pharmaceutical Co., Ltd. for solid tumor treatment. Preclinical studies confirm its selective targeting of CDK4/6 and DYRK2, a eukaryotic CMGC family kinase.

In palbociclib-resistant cell lines, TSL2109 downregulates cell cycle-related proteins and DYRK2 pathway ribosomal synthesis regulators (RRS1, CDK2), and upregulates p53, thus exerting synergistic antitumor effects and overcoming resistance to enzalutamide and palbociclib.

As a small-molecule inhibitor with novel targets, structure and mechanism, TSL2109 blocks tumor cell cycle progression independently of hormonal signaling. Preclinical studies show it overcomes AR inhibitor resistance, meeting unmet needs for prostate cancer patients progressing after AR inhibitor therapy. It also reduces CDK2 activity and blocks CDK4/6 compensatory mechanisms, reversing resistance to CDK4/6 inhibitors, providing a new option for HR+/HER2- advanced breast cancer patients.

Participants Dose-Escalation Phase: Advanced solid tumor patients, prioritizing metastatic castration-resistant prostate cancer (mCRPC) and HR+/HER2- advanced breast cancer.

Dose-Expansion Phase:

Cohort A/C: mCRPC; Cohort B/D: HR+/HER2- advanced breast cancer. Treatment Regimens C0 Cycle (3 days): Single oral dose on Day 1 morning under fasting, followed by 72-hour observation.

C1 Cycle (28 days): Daily fasting oral dosing (QD) for 3 weeks, then 1-week rest. Participants may continue treatment if no DLT and potential clinical benefit.

Dose escalation to a pre-established tolerable level is allowed per investigator-sponsor agreement if well-tolerated and likely beneficial. Treatment continues until disease progression, intolerable toxicity or new antitumor therapy. The Dose-Expansion Phase uses the same regimen as C1.

Missed Dose: Make-up within 8 hours; skip if delayed over 8 hours. Notes: Once MTD is determined, participants dosed above MTD will be adjusted to MTD. All doses are administered orally under fasting conditions.

Read the detailed description

TSL2109 is a novel dual-target inhibitor of Cyclin-Dependent Kinase 4/6-Dualspecificity tyrosine-(Y)-phosphorylation Regulated Kinase 2 (CDK4/6-DYRK2) developed by Jiangsu Tasly Diyee Pharmaceutical Co., Ltd., intended for the treatment of solid tumors. Preclinical studies have demonstrated that TSL2109 selectively targets CDK4/6 and DYRK2, where DYRK2 (Dual-specificity tyrosine-phosphorylation regulated kinase 2) belongs to the CMGC family of the eukaryotic kinome. In vitro treatment of palbociclib-resistant cell lines with TSL2109 induced downregulation of cell cycle-related proteins and downstream ribosomal synthesis regulatory proteins of the DYRK2 signaling pathway, including Regulator of Ribosome Synthesis 1 (RRS1) and Recombinant Cyclin-Dependent Kinase 2 (CDK2), while simultaneously upregulating Recombinant Tumor Protein P53 (p53), thereby exerting synergistic antitumor effects and overcoming resistance to enzalutamide and palbociclib.This product is a selective small-molecule inhibitor of DYRK2 and CDK4/6 based on novel anticancer targets, novel chemical structure, and novel mechanism of action.

Selective inhibition of DYRK2 and CDK4/6 can block tumor cell cycle progression independent of hormonal signaling pathways. In vitro and in vivo animal experiments have demonstrated promising efficacy in overcoming resistance to androgen receptor (AR) inhibitors, addressing the unmet clinical need for prostate cancer patients who have progressed following AR inhibitor therapy. Secondly, selective inhibition of DYRK2 can reduce CDK2 activity and block CDK4/6 compensatory mechanisms, with in vitro and in vivo animal experiments showing efficacy in overcoming resistance to CDK4/6 inhibitors. This addresses the treatment challenge for patients with HR+/HER2- advanced breast cancer who have progressed following CDK4/6 inhibitor therapy, providing a novel therapeutic option for HR+/HER2- breast cancer patients.

Participants:

Dose-Escalation Phase: Patients with advanced solid tumors, with priority given to those with metastatic castration-resistant prostate cancer (mCRPC) and HR+/HER2- advanced breast cancer.

Dose-Expansion Phase:

Cohort A and/or Cohort C: Metastatic castration-resistant prostate cancer (mCRPC) Cohort B and/or Cohort D: HR+/HER2- advanced breast cancer C0 Treatment Cycle (3 days): Oral administration on the morning of Day 1 under fasting conditions, followed by 72-hour observation.

C1 Treatment Cycle (28 days): Multiple doses administered under fasting conditions, with daily dosing (QD) for 3 weeks followed by a 1-week treatment-free interval. If no dose-limiting toxicity (DLT) occurs during the DLT observation period and the investigator determines that continued treatment may provide benefit, the participant may continue receiving study treatment.

During subsequent treatment, if the investigator determines based on available safety and efficacy data that increasing the dose may enhance potential benefit for the participant, and the participant has demonstrated good tolerability, the dose level may be escalated to a previously established tolerable dose following discussion between the investigator and sponsor. Treatment may continue until disease progression, intolerable toxicity, or initiation of new antitumor therapy.

Dose-Expansion Phase: The same dosing regimen as C1. Missed Dose: Make-up dosing is permitted within 8 hours; if more than 8 hours have elapsed, the missed dose should be skipped.

Notes:

Participants previously enrolled at dose levels above the maximum tolerated dose (MTD) will have their subsequent doses adjusted to the MTD dose level once the MTD is established.

Administered orally under fasting conditions.

03

Conditions studied

  • Metastatic Castration-Resistant Prostate Cancer Patients

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years.
  2. or cytologically confirmed advanced solid tumors, with failure of prior standard therapy, or no available standard therapy, or currently unsuitable for standard therapy, and not amenable to surgery or radiotherapy with curative intent. Priority will be given to patients with castration-resistant prostate cancer (mCRPC) and HR+/- advanced breast cancer.
  3. (Dose-Escalation Phase) At least one evaluable or measurable tumor lesion per Version 1.1; (Dose-Expansion Phase) At least one measurable tumor lesion per RECIST Version 1.1 (tumor lesions located in prior radiation fields or other locally treated sites generally do not qualify as unless there is clear progression or persistence three months after radiotherapy).
  4. ≥3 months.
  5. performance status score of 0 to 1.

Metastatic Castration-Resistant Prostate Cancer (mCRPC):

Castration status at screening: (1) Currently receiving androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or history of bilateral orchiectomy. (2) Serum total testosterone ≤1.7 nmol/L (50 ng/dL) at screening. Additionally, progression documented by one or more of the following three criteria: ① PSA progression defined as PSA >1 ng/mL with two consecutive increases >50% from baseline at least 1 week apart; ② Soft tissue disease progression per RECIST 1.1; ③ Bone disease progression per PCWG3, defined as two or more new bone lesions on bone scan. Priority will be given to end-line patients who have received prior androgen receptor inhibitors and have received chemotherapy or are chemotherapy-intolerant or chemotherapy-refusing.

HR+/HER2- Breast Cancer:

① Histologically or cytologically confirmed HR-positive, HER2-negative breast cancer (determined from the most recent tumor sample [primary or metastatic] with histological confirmation of HR+/HER2- status. To meet HR+ disease requirements, breast cancer must express estrogen receptor [ER], with or without progesterone receptor co-expression), locally advanced or recurrent/metastatic breast cancer in female patients. ② Prior exposure to CDK4/6 inhibitors (e.g., abemaciclib, palbociclib, etc.).

Exclusion criteria

Exclusion Criteria:

  1. Clinically symptomatic central nervous system (CNS) or , or other evidence indicating uncontrolled CNS or leptomeningeal metastases, judged by the investigator as unsuitable for enrollment.
  2. Diagnosis of another invasive within the past 2 years, except for radically treated non-melanomatous skin cancer or superficial urothelial carcinoma, cutaneous basal cell or squamous cell carcinoma, superficial bladder cancer, prostate carcinoma in situ, papillary thyroid carcinoma, cervical carcinoma in situ, or breast carcinoma in situ.
  3. gastrointestinal dysfunction that may affect drug intake, transport, or absorption, such as inability to take oral medications, uncontrolled nausea or vomiting, history of extensive gastrointestinal resection, unresolved recurrent diarrhea, untreated gastric conditions requiring long-term proton pump inhibitor therapy, Crohn's disease, ulcerative colitis, intestinal obstruction, etc.
  4. Imaging (CT or MRI) showing tumor invasion of major blood vessels (e.g., aorta, pulmonary arteries/veins, vena cava, etc.) with assessed bleeding risk.
  5. Interstitial lung disease, pneumonitis, or pulmonary fibrosis, assessed by the investigator as unsuitable for enrollment.
  6. History of deep vein thromboembolism.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    Experimental arm/Group: TSL2109 capsules

    Dose Group 1: 50mg, 1 subject Dose 2: 100mg, 1 subject Dose 3: 200mg, 3-9 subjects Dose 4: 300mg, 3-9 subjects Dose 5: 400mg, 3-9 subjects Dose 6: 500mg, 3-9 subjects

    Drug: Treatment arm: TSL2109 capsules。Oral administration。

Interventions

  • DrugTreatment arm: TSL2109 capsules。Oral administration。

    Dosage and Administration: Oral administration on an empty stomach, once daily. Applicable to 50mg (2 capsules of 25mg), 100mg (1 capsule of 100mg), 200mg (2 capsules of 100mg), 300mg (3 capsules of 100mg), 400mg (4 capsules of 100mg), and 500mg (5 capsules of 100mg) dose groups. Duration of Treatment: Multiple dosing, with each treatment cycle consisting of 28 days.

    Also known as: DYRK2-CDK4/6

06

What researchers measure

Primary outcomes

  1. Tolerability assessment

    determine the dose-limiting toxicity (DLT)

    Time frame: Within 31 days after dosing

  2. Tolerability assessment

    maximum tolerated dose (MTD) (if obtainable)

    Time frame: Within 31 days after dosing

  3. Tolerability assessment

    the recommended Phase II dose (RP2D)

    Time frame: Within 31 days after dosing

Secondary outcomes

  1. Drug concentration of 2109 in participant blood

    Cmax

    Time frame: Within 31 days after dosing

  2. Drug concentration of 2109 in participant blood

    Tmax

    Time frame: Within 31 days after dosing

  3. Drug concentration of 2109 in participant blood

    t1/2

    Time frame: Within 31 days after dosing

07

Study locations

1 of 1 sites recruiting
  • Shanghai Gaobo Cancer Hospital (China Pharmaceutical University)
    Shanghai, Shanghai Municipality 200003, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — IPD will not be shared to protect patient privacy, uphold informed consent, and comply with applicable data protection regulations and ethical research standards.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2026, 10 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 10 months is below that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2026
First posted
Apr 7, 2026
StartActual
Feb 20, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07514065
Responsible party
Sponsor
First posted
Apr 7, 2026
Start date
Feb 20, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 7, 2026

Study contacts

Rui Liu
Contact
liurui383@taslypharma.com
00-86-022-86343626
Jin Li, Doctor
principal investigator · Shanghai Gobroad Cancer Hospital (China Pharmaceutical University)
Shu K Qin, Doctor
study chair · Nanjing Tianyinshan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion